Colorectal Cancer Therapeutics in Major Developed Markets to 2020 – Increased Uptake of High Priced Drugs to Offset the Impact of Generics – Acute Market Reports

Colorectal Cancer Therapeutics in Major Developed Markets to 2020 – Increased Uptake of High Priced Drugs to Offset the Impact of Generics

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Colorectal Cancer Therapeutics in Major Developed Markets to 2020 – Increased Uptake of High Priced Drugs to Offset the Impact of Generics”, which provides in-depth analysis of the Colorectal Cancer (CRC) therapeutics market in the eight major geographies of the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The report provides an estimation of the market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth pipeline analysis, and deal analysis.

Browse Full Report Visit :- http://www.acutemarketreports.com/report/colorectal-cancer-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-high-priced-drugs-to-offset-the-impact-of-generics

The CRC therapeutics market in the eight major markets is expected to grow at a Compound Annual Growth Rate (CAGR) of 1.8% to $9.4 billion by 2020. The US had the largest market share in 2013, equivalent to a global share of 44.1%, followed by Japan and Germany with 14.7% and 11.9% respectively. Spain had the lowest market share of the leading eight at 4.1%. All markets covered in the report are expected to witness a slower growth rate than Japan, which will grow at a CAGR of 5%. However, this moderate growth will be stymied by the expected uptake of lower-priced biosimilar versions of bevacizumab and cetuximab due to the expiration of the patents of Avastin and Erbitux in the latter half of the forecast period. Also expected is the launch of generic versions of capecitabine, which will also affect the market. However, this will be offset by the launch of premium-priced emerging therapies.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the eight major markets: the US, the UK, France, Germany, Spain, Italy, Japan and Canada. It includes –

– A brief introduction to CRC, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms

– In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy

– A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target

– Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type

Reasons to buy

The report will enhance your decision-making capability by allowing you to –

– Understand the CRC pipeline and the factors that indicate that it is becoming more innovative

– Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be

– Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates

– Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market

– Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Browse All Reports of This Category :- http://www.acutemarketreports.com/category/pharmaceutical-market

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 9
2.1 Colorectal Cancer 9
2.2 Symptoms 9
2.3 Epidemiology 9
2.4 Pathophysiology 10
2.4.1 Histology 10
2.4.2 Genetic Basis 10
2.4.3 Etiology of Colorectal Cancer 10
2.5 Diagnosis 12
2.5.1 Digital Rectal Examination 12
2.5.2 Fecal Occult Blood Test 12
2.5.3 Flexible Sigmoidoscopy 12
2.5.4 Colonoscopy 13
2.5.5 Virtual Colonoscopy 13

3 Marketed Products 22
3.1 Key Marketed Products 22
3.1.1 Immunotherapies 22
3.1.2 Targeted Therapies 25
3.1.3 Hyperthermic Intraperitoneal Chemotherapy 30
3.2 Heat Map for Marketed Products 31

To Get Complete Report @ http://www.acutemarketreports.com/report/colorectal-cancer-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-high-priced-drugs-to-offset-the-impact-of-generics

About Us:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the worlds most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Contact Us :

Name : Chris Paul

ACUTE MARKET REPORTS

Designation : Global Sales Manager

Toll Free(US/CANADA): +1-855-455-8662

Email :  sales@acutemarketreports.com

Website : http://www.acutemarketreports.com